Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Non-Current Liabilities (2021 - 2025)

Senti Biosciences has reported Total Non-Current Liabilities over the past 5 years, most recently at $37.5 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $37.5 million for Q4 2025, down 10.71% from a year ago — trailing twelve months through Dec 2025 was $37.5 million (down 10.71% YoY), and the annual figure for FY2025 was $37.5 million, down 10.71%.
  • Total Non-Current Liabilities for Q4 2025 was $37.5 million at Senti Biosciences, up from $37.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for SNTI hit a ceiling of $53.3 million in Q4 2022 and a floor of $36.3 million in Q2 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $43.8 million (2023), compared with a mean of $43.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 46.73% in 2022 and later decreased 20.04% in 2024.
  • Senti Biosciences' Total Non-Current Liabilities stood at $36.3 million in 2021, then skyrocketed by 46.73% to $53.3 million in 2022, then dropped by 1.37% to $52.6 million in 2023, then decreased by 20.04% to $42.0 million in 2024, then dropped by 10.71% to $37.5 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $37.5 million (Q4 2025), $37.0 million (Q3 2025), and $36.3 million (Q2 2025) per Business Quant data.